Objective: To assess the morbidity and efficacy of repeat cryoablation(CA) in the treatment of localized prostate cancer.

Methods: Twenty-seven patients with median age of 71 years (range: 48-80) who underwent repeat CA between April 2003 and April 2011 at a single institution were included.  The median initial prostate-specific antigens (PSA) and Gleason values were 6.2 ng/ml (range: 4-23.6) and 7 (range: 6-9), respectively. Twenty-four patients underwent two CA treatments, and 3 patients underwent 3 CA treatments.  Pre- and perioperative parameters and oncological and functional outcomes were evaluated.

Results: No intraoperative complications occurred. After the first CA, PSA was undetectable in 10  patients, and the median nadir PSA value was 0.65 ng/ml (range: 0.1-4.9). After the second CA, 4 patients had undetectable PSA, and the median nadir PSA value was 1.25 ng/ml (range:  0.2-7.9). For patients who underwent a third CA treatment, no patients had undetectable PSA, and the subsequent median nadir PSA value was 1.6 ng/ml (range: 0.4-4.5). Two patients had incontinence (1 pad per day) following repeat CA. One patient had urinary retention after the third CA treatment, and 1 had urethral stricture. Of 6 patients who were potent before CA, 5 could achieve erection with medication after the second treatment. The mean hospitalization and follow-up periods were 1 day (range:  0-2) and 51.5 months (range: 11-96), respectively.

Conclusion: Repeat CA successfully reduced PSA levels, and complications were modest. We conclude that repeat CA is a feasible, safe, and effective treatment option for localized prostate cancer.

Conference Title

24th Turkish international Urology meeting 2015

Conference Country

Palestine

Conference Date

Jan. 1, 2015 - Jan. 1, 2015

Conference Sponsor

Turkish association of urology